Safety of endovascular treatment in acute stroke patients taking oral anticoagulants

Timo Uphaus¹, Oliver C Singer², Joachim Berkefeld³, Christian H Nolte⁴, Georg Bohner⁵, Kurt Niederkorn⁶, Hannes Deutschmann⁷, Hans-Peter Haring⁷, Johannes Trenkler⁹, Tobias Neumann-Haefelin¹⁰, Erich Hofmann¹¹, Anett Stoll¹², Albrecht Bormann¹³, Matthias Bussmeyer¹⁴, Aanastasios Mpotsaris¹⁵, Arno Reich¹⁶, Martin Wiesmann¹⁷, Gabor C Petzold¹⁸, Horst Urbach¹⁹, Sebastian Jander²⁰, Bernd Turowski²¹, Christian Weimar²², Marc Schlamann²³, David S Liebeskind²⁴, Sonja Gröeschel¹, Stephan Boor²⁵ and Klaus Gröschel¹

Abstract

Background: The endovascular treatment of acute cerebral ischemia has been proven beneficial without major safety concerns. To date, the role of endovascular treatment in patients treated with oral anticoagulants, which may be associated with periprocedural intracranial bleeding, remains uncertain.

Aims: The objective of the current analysis is to evaluate the safety of endovascular treatment in patients treated with oral anticoagulants.

Methods: The ENDOSTROKE-Registry is a commercially independent, prospective observational study in 12 stroke centers in Germany and Austria collecting pre-specified variables about endovascular stroke therapy.

Results: Data from 815 patients (median age 70 (interquartile range (IQR) 20), 57% male) undergoing endovascular treatment with known anticoagulation status were analyzed. A total of 85 (median age 76 (IQR 8), 52% male) patients (10.4%) took vitamin-K-antagonists prior to endovascular treatment. Anticoagulation status as measured with international normalized ratio was above 2.0 in 31 patients. Intracranial hemorrhage occurred in 11.8% of patients taking oral anticoagulants.
vitamin-K-antagonists compared to no-vitamin-K-antagonists (12.2%, \( p = 0.909 \)). After adjustment for confounding factors which were unbalanced at univariate level such as NIHSS and age, anticoagulation status was not found to significantly influence clinical outcome (modified Rankin Scale 3–6) and occurrence of intracranial hemorrhage in a multivariate logistic regression analysis.

**Conclusion:** Prior use of vitamin-K-antagonists was not associated with a higher rate of periprocedural intracranial hemorrhage after endovascular treatment or worse outcome. Endovascular treatment should be considered as an important treatment option in patients taking vitamin-K-antagonists.

**Keywords**
Ischaemic stroke, intervention, antithrombotic

Received: 17 July 2016; accepted: 26 September 2016

**Introduction**
Sufficient anticoagulation is a contraindication for intravenous thrombolysis (IVT) as it carries an additional risk of major bleeding. Current guidelines suggest starting IVT only in patients taking vitamin-K-antagonists (VKA) with INR of 1.7 or less at time of presentation with acute ischemic stroke.\(^1\) Therefore, many patients at high risk for an embolic stroke might not be suitable for IVT. Recently, endovascular treatment (EVT) applying mostly stent-retriever devices has been proven beneficial.\(^2,3\) However, the role of EVT in acute stroke patients taking VKA – still highly prescribed compared to Non-vitamin K antagonist oral anticoagulants (NOACs)\(^4\) – remains uncertain, because this group of patients was not considered in most randomized trials and previous interventional studies.\(^2\)

**Aims**
The ENDOvascular STROKE treatment (ENDOSTROKE) registry was launched to accompany the spreading use of EVT in German and Austrian stroke centers.\(^5\) The current analysis evaluates the efficacy and safety of EVT in patients under VKA therapy.

**Methods**
The ENDOSTROKE-Registry represents an investigator-initiated observational, international, multicenter study. The study focuses on adult patients who underwent thrombectomy for acute ischemic stroke. The study protocol was approved by the ethics committee of the University Medical Center Frankfurt and the local ethic committees. ENDOSTROKE is registered with ClinicalTrials.gov as NCT01399762.

**Data analysis**
Baseline characteristics of the study population were recorded and an outcome follow-up on the basis of the modified Rankin Scale (mRS) was performed at least 90 days after intervention. The main outcome variables were the occurrence of any intracranial hemorrhage (ICH) and symptomatic ICH (sICH: according to the European Cooperative Acute Stroke Study-II (ECASS-II); online-only data supplement).

**Statistical analysis**
Mann–Whitney U, \( \chi^2 \), or Fisher exact test were used for univariate analysis. Multivariate analysis used a binary logistic regression model (details are given in the online-only data supplement). Statistical analysis was performed using SPSS, version 22 (IBM, Armonk, NY) with \( p \) values of \( p < 0.05 \) considered significant.

**Results**
Out of 815 patients, 85 patients (10.4%) took VKA prior to EVT. Of 83 patients with valid international normalized ratio (INR) data prior to EVT, 31 patients (37%) were sufficiently anticoagulated (INR > 2), 7 of which presented with an INR > 3.0 (8%). Patients taking VKA were significantly older (median age 76 (IQR 8) vs. no-VKA 69 (20)) and more frequently had a history of atrial fibrillation, arterial hypertension, and cardiovascular diseases. Additional patient characteristics showed no significant differences between VKA and no-VKA groups at baseline (online-only data supplement Table 1).

Any ICH occurred in 11.8% of VKA and in 12.2% of no-VKA patients (Table 1). sICH was also equally distributed between both groups (71% VKA vs. 89% no-VKA). No bleeding complications were reported in VKA patients.

Patients taking VKA with INR < 2.0 received IVT more frequently than those taking VKA with an INR ≥ 2.0 (\( n = 20 \) (38.5%) vs. \( n = 2 \) (6.5%), \( p = 0.002 \)). We detected no association between an
increase in INR and an increased occurrence of ICH (online-only data supplement Table 2).

Good clinical outcome (mRS 0-2) occurred in 37.8% of all patients and was found to be significantly different between groups (25.9% VKA vs. 39.2% no-VKA, Table 1). After adjustment for potential confounding factors within the baseline, periprocedural characteristics and variables which were unbalanced at univariate level, neither clinical outcome nor occurrence of any ICH was significantly influenced by the prior use of VKA (Table 2).

### Discussion

Our analysis of the prospective ENDOSTROKE Registry detected no increased risk for periprocedural ICH after EVT in patients with prior VKA treatment. The observed rates of sICH (7.1%) and any ICH (11.8%) are comparable to the bleeding rates reported in a meta-analysis of recent thrombectomy trials.2 Moreover, the proportion of sICH is consistent with bleeding rates reported by retrospective studies in VKA (6%)6 and NOAC (4%)7 patients, although these studies report higher rates of any ICH in VKA (26%)6 and NOAC (46%)7 patients. These results make a case for performing an EVT even if the patient is taking VKA and argue against a priori exclusion of VKA-treated patients. However, one should keep in mind that 63% of our VKA-patients had an INR < 2.0 at admission, which may not be

### Table 1. Periprocedural characteristics, safety and functional outcome

| Variable                  | VKA  | No-VKA | p     |
|---------------------------|------|--------|-------|
| IVT                       | 22 (25.9) | 533 (73.1) | <0.001 |
| Time between symptom onset and start of angiography (min) | 200 (132) | 200 (107) | 0.587 |
| Location of vessel occlusion |     |        | 0.405 |
| M1                        | 43 (52.4) | 361 (50.0) |     |
| M2                        | 3 (3.7) | 37 (5.1) |     |
| Carotid T occlusion       | 13 (15.9) | 129 (17.9) |     |
| ICA                       | 3 (3.7) | 30 (4.2) |     |
| Basilar artery            | 19 (23.2) | 118 (16.3) |     |
| Vertebral artery, V4      | 0 | 13 (1.8) |     |
| Other                     | 1 (1.2) | 34 (4.7) |     |
| TIMI, start of angiography |     |        | 0.001 |
| TIMI 0-1                  | 71 (83.5) | 684 (93.7) |     |
| TIMI 2-3, unknown         | 14 (16.5) | 46 (6.3) |     |
| TICI, end of angiography  |     |        | 0.094 |
| Grade 0–2a                | 23 (29.9) | 140 (21.5) |     |
| Grade ≥2b                 | 54 (70.1) | 512 (78.5) |     |
| Any ICH                   | 10 (11.8) | 89 (12.2) | 0.909 |
| Asymptomatic ICH          | 4 (4.7) | 24 (3.3) | 0.523 |
| Symptomatic ICH           | 6 (7.1) | 65 (8.9) | 0.568 |
| Puncture site complication| 0 | 12 (1.6) | 0.234 |
| mRS 90 d                  |     |        | 0.017 |
| 0–2                      | 22 (25.9) | 286 (39.2) |     |
| 3–6                      | 63 (74.1) | 444 (60.8) |     |

Note: Data presented as number (%) or median (IQR). p < 0.05 considered significant.

VKA: vitamin-K-antagonists; No-VKA: no vitamin-K-antagonists; IVT: intravenous thrombolysis; ICA: internal carotid artery; TIMI: thrombolysis in myocardial infarction score; TICI: Thrombolysis in cerebral infarction score; ICH: intracranial hemorrhage; mRS: modified Rankin Scale.

### Table 2. Factors determining functional outcome after 90 d and occurrence of any ICH

| Outcome and Predictor | 95% CI  | Odds ratio | p     |
|-----------------------|---------|------------|-------|
| mRS 3-6 90 d          |         |            |       |
| NIHSS (admission)     | 1.075–1.138 | 1.106 | <0.001 |
| Age                   | 1.017–1.051 | 1.034 | <0.001 |
| Diabetes mellitus     | 1.110–3.029 | 1.834 | 0.018 |
| TICI, end of angiography | 0.533–0.698 | 0.610 | <0.001 |
| Any ICH               |         |            |       |
| Diabetes mellitus     | 1.116–3.233 | 1.899 | 0.018 |
| TICI end of angiography | 0.350–0.980 | 0.586 | 0.042 |

mRS: modified Rankin Scale; VKA: vitamin-K-antagonist; NIHSS: National Institute of Health Stroke Scale; TICI: thrombolysis in cerebral infarction score.

Note: p < 0.05 considered significant.
representative of patients on VKA in other regions in Europe and North America\(^3\); thus, the lack of difference in ICH in VKA patients should be interpreted with caution. Nonetheless, we detected no association between an increase in INR and an increased occurrence of ICH.

The prior use of VKA was not associated with an unfavorable outcome in multivariate analysis. In univariate comparison, an overall unfavorable outcome (mRS 3-6) was reported in 74.1% of all VKA-treated patients after EVT (no-VKA 60.8%). After adjustment for confounding factors, this difference was no longer apparent and can be mainly attributed to the non-equivalent distribution of patient age.\(^2,5\)

This study faces the limitations of a non-randomized, observational registry. However, EVT in patients taking VKA appears to be safe and should therefore be considered as a treatment option in acute ischemic stroke. Further investigations are still needed to clarify the adjunctive use of IVT and the role of NOACs.

**Acknowledgments**

We thank Cheryl Ernest for proofreading the manuscript.

**Authors’ contribution**

Manuscript preparation and data analysis: TU, OCS, SG, KG. Study design: OCS, JB, CHN, TN. Data collection: all authors. Blinded angiographic rating DSL.

**Declaration of conflicting interests**

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Speaker honoraria from Boehringer Ingelheim, Bayer Healthcare, BMS (SJ, CW, KG); Daiichi Asubio, Penumbra (CW); Daichii Sankyo (CW, KG); Pfizer (SJ, KG). BT Scientific advisor for Acandis. The other authors report no conflicts.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**References**

1. Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. Scientific Rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American heart association/American stroke association. *Stroke* 2016; 47: 581–641.
2. Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet* 2016; 387: 1723–1731.
3. Mulder MJ, Berkhemer OA, Fransen PS, et al. Treatment in patients who are not eligible for intravenous alteplase: MR CLEAN subgroup analysis. *Int J Stroke* 2016; 11: 637–645.
4. Weitz JI, Semchuk W, Turpie AG, et al. Trends in prescribing oral anticoagulants in Canada, 2008–2014. *Clin Ther* 2015; 37: 2506–2514 e4.
5. Singer OC, Haring HP, Trenkler J, et al. Age dependency of successful recanalization in anterior circulation stroke: the ENDOSTROKE study. *Cerebrovasc Dis* 2013; 36: 437–445.
6. Seiffge DJ, Hooff RJ, Nolte CH, et al. Recanalization Therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome. *Circulation* 2015; 132: 1261–1269.
7. Purrucker JC, Wolf M, Haas K, et al. Safety of Endovascular thrombectomy in patients receiving non-vitamin k antagonist oral anticoagulants. *Stroke* 2016; 47: 1127–1130.
8. Pokorney SD, Simon DN, Thomas L, et al. Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry. *Am Heart J* 2015; 170: 141–148, 8 e1.